Abstract 1251P
Background
Neutrality trial aims to analyze the prognostic role of blood biomarkes such as NLR (neutrophils to lymphocytes ratio), SII (Systemic Inflammatory Index-NLR x platelets), dNLR (neutrophil to leukocytes - neutrophil ratio) and LIPI (Lung Immune Prognostic Index) in stage III NSCLC patients (pts) treated with radiochemotherapy (RT-CHT) followed by Durvalumab (Cohort A), and in pts treated with RT-CHT alone (Cohort B).
Methods
NEUTRALITY is a retrospective multicentric observational study (ESR-19-20410). Blood count tests were recorded at the end of RT-CHT for Cohort B and during Durvalumab course for Cohort A. Different cut-offs of NLR, dNLR and SII were considered, based on the median values observed. Three LIPI index groups were analyzed: good (dNLR ≤ 3 and LDH ≤ UNL), intermediate (dNLR>; 3 or LDH ≥ UNL) and poor (dNLR>; 3 and LDH ≥ UNL). We performed a Cox-Regression analysis to correlate these biomarkers to overall survival (OS) and progression-free survival (PFS).
Results
Overall 190 pts (96 in Cohort A and 94 in Cohort B) were enrolled from 35 Italian Centers. Details of pts are shown in the table. For cohort A, we observed a significant correlation between baseline NLR, SII and dNLR with PFS: p 0.017, p 0.03 and p 0.018, respectively. LIPI was found to correlate with PFS too, with a better PFS in the good group, as expected (p 0.04). No correlation was found between these biomarkers and PFS and OS in Cohort B. Table: 1251P
Patients characteristics
| Cohort A patients (%) 96 | Cohort B patients (%) 94 | |
| Sex MF | 62 (64.5%)34 (35.5%) | 66 (70%)28 (30%) |
| Smoke YesNo | 85 (88%)9 (12%) | 85 (90%)9 (10%) |
| Age years MedianRange | 68 y44-83 | 66 y42-84 |
| Histology AdenocarcinomaSquamocellularOthers | 54 (56%)39 (41%)3 (3%) | 49 (52%)39 (41%)6 (7%) |
| PD-L1 expression 01-49≥ 50Not tested | 12 (12.5%)41 (43%)30 (31%)13 (13.5%) | 11 (12%)15 (16%)9 (10%)59 (62%) |
| Stage disease IIIAIIIBIIIC | 35 (36.5%)48 (50%)13 (13.5%) | 39 (41%)44 (47%)11 (12%) |
| ECOG PS 012 | 59 (61.5%)35 (37.5%)1 (1%) | 60 (64%)34 (36%)0 |
Conclusions
Our analysis suggests that blood inflammatory biomarkers can have a prognostic role for stage III NSCLC treated as per Pacific regimen. Further analysis are still ongoing to compare the two cohorts.
Clinical trial identification
ESR-19-20410.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1292P - A national real-world analysis of ROS1+ metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019)
Presenter: Gaelle Rousseau Bussac
Session: Poster session 05
1293P - Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial
Presenter: Ben Solomon
Session: Poster session 05
1294P - Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry
Presenter: Arianna Marinello
Session: Poster session 05
1295P - EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI
Presenter: Elena Garralda
Session: Poster session 05
1296P - A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification
Presenter: Caicun Zhou
Session: Poster session 05
1297P - A phase II study of pyrotinib combined with apatinib in first-line treatment of advanced non-small cell lung cancer patients with primary HER-2 mutations/amplification
Presenter: Wenxin Jiang
Session: Poster session 05
1299P - First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
Presenter: Alessandro Di Federico
Session: Poster session 05
1300P - Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
Presenter: Marcel Wiesweg
Session: Poster session 05
1301P - BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database
Presenter: Alessandro Russo
Session: Poster session 05